Novel proteomics approach for functional identification of regulators of cancer drug response and apoptosis in ex vivo tissue cultures of human colorectal cancer
M. M. Borner , F. Pirnia Borner , D. C. Betticher , B. Gloor
Journal of Clinical Oncology 23 9658 -9658
2005
Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras-unmutated, locally advanced rectal cancer (LARC): A randomized multicenter phase II trial (SAKK 41/07).
D. Helbling , G. Bodoky , O. Gautschi , H. Sun
Journal of Clinical Oncology 29 3546 -3546
4
2011
Everolimus as first-line therapy in nonrapidly progressive metastatic castration-resistant prostate cancer (mCRPC): A multicenter phase II trial (SAKK 08/08).
A. Templeton , C. Rothermundt , R. Cathomas , D. Baertschi
Journal of Clinical Oncology 29 4588 -4588
4
2011
Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)
A. D. Roth , R. Maibach , S. Falk , R. Stupp
Journal of Clinical Oncology 22 4020 -4020
55
2004
The impact of the irinotecan (IRI) schedule on quality of life in combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research
M. M. Borner , J. Bernhard , D. Dietrich , R. Popescu
Journal of Clinical Oncology 22 8120 -8120
9
2004
A multicentre inter-observer study on tumour budding using a 10HPF method in colorectal cancer: a study from the Swiss Association of Gastrointestinal Pathology (SAGIP)
Luigi Tornillo , Viktor Kölzer , Klaus Dirschmid , Marionna Myrta Cathomas
1
2014
Management of infusion reactions in clinical trials and beyond: the US and EU perspectives.
Anthony J Cmelak , Markus Borner , M Wasif Saif , Florian Lordick
Oncology 23 ( 2) 18 -25
10
2009
Treatment landscape of metastatic pancreatic cancer.
Alexander Meisel , Markus Borner , Thomas Winder , Ralph Fritsch
Cancer Treatment Reviews 96 102180
1
2021
Chimiothérapie palliative ou plutôt soins palliatifs
Markus Borner , Daniel Rauch
Forum Médical Suisse 15 ( 16) 334 -339
2015
Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer
Stephen Chan , Max E Scheulen , Stephen Johnston , Klaus Mross
Journal of Clinical Oncology 23 ( 23) 5314 -5322
556
2005
Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
Ullrich Graeven , Karsten Ridwelski , Maja Artandi , Pilar Espana
Oncology Reports 13 ( 4) 681 -688
4
2005
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Karin Ribi , Dieter Koeberle , Jan C. Schuller , Hanspeter Honegger
Supportive Care in Cancer 17 ( 8) 1109 -1116
17
2009
Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study
Benjamin Kasenda , Annatina Bass , Dieter Koeberle , Bernhard Pestalozzi
BMC Cancer 14 ( 1) 728 -728
27
2014
Sirolimus and intraoperative hyperthermic peritoneal chemoperfusion with mitomycin-C do not impair healing of bowel anastomoses.
Oliver J. Wagner , Roman A. Inglin , Sonja Bisch-Knaden , Daniel Mettler
Transplant International 21 ( 6) 554 -563
6
2008
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Christoph Rochlitz , , Martin Bigler , Roger von Moos
BMC Cancer 16 ( 1) 780 -780
31
2016
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
Andreas Mueller , Katharina Buser , Markus Borner , Urban Novak
BMC Cancer 17 ( 1) 265 -265
10
2017
An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer
Marc Salzberg , Christoph Rochlitz , Rudolf Morant , George Thalmann
Onkologie 30 ( 7) 355 -360
33
2007
Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas
Eva Karamitopoulou , Luigi Tornillo , Inti Zlobec , Lukas Cioccari
American Journal of Clinical Pathology 130 ( 5) 780 -786
46
2008
Bile duct infarction following intraarterial hepatic chemotherapy mimicking multiple liver metastasis: report of a case and review of the literature.
Shailesh Shrikhande , Helmut Friess , Jõrg Kleeff , Adrien Tempia
Digestive Diseases and Sciences 47 ( 2) 338 -344
4
2002
Offener Brief an die Schweizer Bundesräte Ueli Maurer (Bundespräsident), Alain Berset (Vorsteher EDI) und Herrn Ignazio Cassis (Vorsteher EDA)
Jrg Barben , Mac M. Schuurmans , Alice Zrcher , Rainer M. Kaelin
Bulletin des Médecins Suisses 100 ( 36) 1189 -1190
2019